Overview
"""Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner."" --Thom Calandra, editor in chief, CBS MarketWatch In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for - tracking the effect of breaking news and the NASDAQ - anticipating drug trial announcements and FDA approvals - assessing the potential market, patent rights, and distribution deals for a drug He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries."
Full Product Details
Author: Tom Abate
Publisher: Henry Holt & Company Inc
Imprint: Owl Books,U.S.
Dimensions:
Width: 14.00cm
, Height: 2.10cm
, Length: 21.70cm
Weight: 0.386kg
ISBN: 9780805075083
ISBN 10: 0805075089
Pages: 304
Publication Date: 01 January 2004
Audience:
General/trade
,
General
Format: Paperback
Publisher's Status: Active
Availability: In Print
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.
Reviews
“An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come.” —Brook H. Byers, partner, Kleiner Perkins Caufield & Byers
An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come. Brook H. Byers, partner, Kleiner Perkins Caufield & Byers An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come. -Brook H. Byers, partner, Kleiner Perkins Caufield & Byers An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come. -- Brook H. Byers, partner, Kleiner Perkins Caufield & Byers An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come. --Brook H. Byers, partner, Kleiner Perkins Caufield & Byers
An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come. -- Brook H. Byers, partner, Kleiner Perkins Caufield & Byers<br>
“An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come.” —Brook H. Byers, partner, Kleiner Perkins Caufield & Byers<br>
Author Information
One of the nation's most influential observers of the biotechnology industry, award-winning technology and health-care reporter Tom Abate writes the weekly BioScope column for the San Francisco Chronicle. He lives in San Leandro, California.
